• Explore /
  • Poster
  • / A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).

Abstract Poster

Authors

null

Neil J. Shah

Memorial Sloan Kettering Cancer Center, New York, NY

Neil J. Shah , Katy Beckermann , Nicholas J. Vogelzang , Shifeng S. Mao , Moshe Chaim Ornstein , Hans J. Hammers , Xin Gao , David F. McDermott , Naomi B. Haas , Hongxia Yan , Vanessa Esquibel , Reshma A. Rangwala , Matthew T Campbell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT04300140

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4511)

DOI

10.1200/JCO.2022.40.16_suppl.4511

Abstract #

4511

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Katy Beckermann

First Author: Katy Beckermann

First Author: Neil J. Shah

First Author: Johanna C. Bendell